Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Year-over-year free cash flow growth rate
Percentile
P36
Within normal range
vs 2Y Ago
-2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -20.10% |
| Q3 2025 | 20.29% |
| Q2 2025 | -13.58% |
| Q1 2025 | -10.20% |
| Q4 2024 | -26.44% |
| Q3 2024 | 52.74% |
| Q2 2024 | -118.09% |
| Q1 2024 | 8.04% |
| Q4 2023 | 10.29% |
| Q3 2023 | -107.88% |
| Q2 2023 | 5.62% |
| Q1 2023 | 2.79% |
| Q4 2022 | -20.38% |
| Q3 2022 | 27.11% |
| Q2 2022 | 21.40% |
| Q1 2022 | -36.50% |
| Q4 2021 | -12.72% |
| Q3 2021 | -932.99% |
| Q2 2021 | 110.27% |
| Q1 2021 | -10.19% |
| Q4 2020 | -0.17% |
| Q3 2020 | 12.71% |
| Q2 2020 | 10.16% |
| Q1 2020 | -32.14% |
| Q4 2019 | -0.67% |
| Q3 2019 | -5.54% |
| Q2 2019 | -3.23% |
| Q1 2019 | -115.12% |
| Q4 2018 | 13.95% |
| Q3 2018 | 5.24% |
| Q2 2018 | -20.57% |
| Q1 2018 | -24.18% |
| Q4 2017 | 18.92% |
| Q3 2017 | -24.90% |
| Q2 2017 | -5.00% |
| Q1 2017 | -27.41% |
| Q4 2016 | 23.68% |
| Q3 2016 | -24.23% |
| Q2 2016 | -18.32% |
| Q1 2016 | -357.04% |